New Medicine Pricing Regulations in Morocco
Morocco has recently enacted significant reforms regarding the pricing of pharmaceuticals, aiming to enhance accessibility and affordability for its citizens. These changes, encapsulated in Decree No. 2.25.631, were officially published in Official Gazette No. 7532 on August 6. The newly established rules fundamentally alter the method by which reference prices for medicines are determined, a move that is expected to have a substantial impact on the country's healthcare landscape.
One of the most noteworthy aspects of this regulatory overhaul is the shift to a pricing system that utilizes the lowest price found among a select group of reference countries. This new approach replaces the former methodology that calculated the Moroccan public selling price based on the average prices of pharmaceuticals within those same markets. By adopting this more competitive pricing strategy, the government aims to lower the financial burden on consumers and ensure that essential medicines remain accessible to all segments of the population.
In addition to adjusting how reference prices are calculated, the decree also reduces the markup applied to imported medications. This reduction is expected to further encourage the availability of affordable medicine within the Moroccan market. Furthermore, the intervals for price reviews have been shortened, allowing for more frequent assessments and adjustments based on market conditions and international pricing trends. Overall, these regulatory changes represent a proactive step by the Moroccan government to improve public health outcomes and ensure that its citizens can access necessary treatments without undue financial strain.
As reported by navlindaily.com.
